NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site

Drug discovery and repurposing of drugs


This research area aims at setting up capabilities for drug discovery and repurposing of existing drugs for COVID-19, and starting pilot projects towards identification of lead molecules (chemicals and biomolecules). Additional aim is to coordinate technologies, capabilities and national expertise, such as data-driven (chemoinformatic) approaches. 

This area consists of 10 individual projects, all together funded by a total of 8,7 MSEK. Led by researchers at Uppsala University, KTH Royal Institute of Technology, Karolinska Institutet and University of Gothenburg.

Coordinator: Jeannette Dypbukt, Karolinska Institutet

Scientific lead: Kristian Sandberg, Uppsala University, and Anna-Lena Gustavsson, Karolinska Institutet

Projects


NEVERMORE COVID – Establishing a drug discovery platform for corona virus disease
Kristian Sandberg, Uppsala University

A high-quality drug repurposing set
Anna-Lena Gustavsson, Karolinska Institutet

Multi-level profiling of Coronavirus-infected cells by combining Viral Entry Assays, Cell Painting, and DrugSEQ
Ola Spjuth, Uppsala University

Spatial single cell mapping of SARS-CoV-2 interacting host proteins for quick and targeted drug repurposing
Charlotte Stadler, KTH

FragCor
Göran Karlsson, University of Gothenburg   

An adaptable therapeutic technology platform to treat SARS-CoV infections in immune suppressed individuals
Sara Mangsbo, Uppsala University

Rapid testing for treatment of Covid-19
Kristina Nyström, Sahlgrenska University Hospital

FRAGMENT2DRUG
Jens Carlsson, Uppsala University

Chemographic characterization of compounds binding to seven identified molecular targets from SARS-CoV-2
Anders Backlund, Uppsala University    

Distributed computing to generate the druggable conformational ensemble of sars-cov-2 proteins
Lucie Delemotte, KTH